Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Brian Godman, Andrew Hill, Steven Simoens, Gisbert Selke, Iva Selke Krulichová, Carolina Zampirolli Dias, Antony P Martin, Wija Oortwijn, Angela Timoney, Lars Gustafsson, Luka Voncina, Hye-Young Kwon, Jolanta Gulbinovic, Dzintars Gotham, Janet Wale, Wânia Cristina da Silva, Tomasz Bochenek, Eleonora Allocati, Amanj Kurdi, Olayinka O. OgunleyeJohanna C Meyer, Iris Hoxha, Admir Malaj, Christian Hierländer, Robert Sauermann, Wouter Hamelinck, Guenka Petrova, Ott Laius, Irene Langner, John Yfantopoulos, Roberta Joppi, Arianit Jakupi, Ieva Greiciute-Kuprijanov, Patricia Vella Bonanno, JF(Hans) Piepenbrink, Vincent de Valk, Magdalene Wladysiuk, Vanda Marković-Peković, Ileana Mardare, Jurij Fürst, Dominik Tomek, Mercè Obach Cortadellas, Corinne Zara, Caridad Pontes, Stuart McTaggart, Tracey-Lea Laba, Øyvind Melien, Durhane Wong-Rieger, SeungJin Bae, Ruaraidh Hill

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. Areas covered: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines. Expert opinion: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges. These include the considerable number of new oncology medicines in development including new gene therapies, new oncology medicines being launched with uncertainty regarding their value, and continued high prices coupled with the extent of confidential discounts for reimbursement. However, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments.

Original languageEnglish
Number of pages23
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Early online date4 Feb 2021
DOIs
Publication statusE-pub ahead of print - 4 Feb 2021

Keywords

  • pricing
  • cancer medicines
  • Europe
  • sustainability
  • healthcare systems
  • multicriteria decision analysis

Cite this